We have a team of experts with incredible knowledge and experience in a variety of backgrounds.

Board and Executive Management

Bionxt’s board and executive management bring significant expertise in science, therapeutics,  business development and growth. Combine the collective skills of the team with an entrepreneurial eye for opportunity and you can see why Bionxt is poised to be a disrupter in the pharmaceutical industry.

Hugh Rogers Profile

Hugh Rogers

Mr. Rogers is an entrepreneur and lawyer with private and public start-up experience in a range of industries and operational roles.

Recent advisory work has focused on public listings and corporate restructuring in the life science (cell therapy and medical device) and natural resource (natural gas co-gen and conventional oil) industries. Mr. Rogers has held several board and executive management positions with junior exchange listed issuers. He holds a bachelor’s degree in Cell Biology and Genetics and a Law degree. He is a member in good standing of the Law Society of British Columbia.

Dr. Florian A. Sahr

Dr. Florian A. Sahr

Dr. Sahr is a German-born and internationally trained leader in drug formulation, technology transfer and new-product manufacturing. 

Dr. Sahr has a strong track record of drug development, including transdermal (“TDS”) and oral dissolvable (“ODF”) delivery systems, as well as the physical and regulatory establishment of GMP and FDA compliant pharmaceutical manufacturing facilities. 

Several employment highlights include his work as Senior Scientist, Head of Manufacturing, Gen-Plus GmbH & Co. KG, Munich, Germany, where he developed TDS and ODF drug formulations and transferred these new formulations and technologies to manufacturing systems and facilities; and his work as Project Manager, Advanced Projects, tesa Labtec GmbH, Langenfeld, Germany, focusing on project management and technology transfer of generic TDS formulations to the company’s manufacturing facilities. 

Dr. Sahr has held the regulated position of Head of Manufacturing according to AMG/AMWHV (German Medicines Act) for the production of clinical trial materials for a number of companies.

Roland Spleiss

Roland Spleiss

Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial professional with over 25 years of experience in planning and building out effective salesforces, strategic realignment, production relocation, and project management, which makes him ideally suited to drive product sales.

In addition to extensive consulting roles, Mr. Spleiss held senior positions including Chief Financial Officer of Wörwag Pharma, a private German health and generic pharmaceutical company with over EUR 200 million in annual sales and 900 employees. He led the company’s strategic professionalization and internationalization of operations, optimization of supply chains and sales processes, and expansion into new European, Asian and Latin American healthcare markets.

Mr. Spleiss’ expertise in production and supply chain management, cost optimization, and sales force and distribution network creation will be invaluable to Bionxt’s commercial strategy and execution.

Joseph Meagher

Joseph Meagher

Chartered Professional Accountant (CPA, CA) since 2008, obtained the Chartered Director (C.Dir.) designation from The Directors College (a joint venture between McMaster University and The Conference Board of Canada) in 2017. Joseph currently serves as the CFO for several publicly listed companies.

Raimar Lobenberg Profile

Prof. Dr. Raimar Löbenberg

Dr. Löbenberg holds a bachelor’s of Science degree in Pharmacy from the Johannes Gutenberg-University, Mainz, Germany and a PhD in Pharmaceutics from the Johann Wolfgang Goethe-University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences. Dr. Löbenberg’s research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis or leishmanasis. He is a cofounder of RS Therapeutics Inc., a foam-based topical drug delivery company.

Dr. Löbenberg’s recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science; and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.

Wolfgang Probst Profile

Wolfgang Probst

Mr. Probst is an experienced management consultant specialized in investment consulting and capitalization.

He’s an expert in mergers and acquisitions, corporate re-organizations, and divestitures and has adroitly brought multiple startups to success. Owing to his superior negotiating skills, he has a proven track record in strategic analysis, which resulted in highly targeted organizational restructuring.

“We have ambitious milestones for Bionxt’s future, and I am confident our team will execute.”

– Hugh Rogers, CEO

Invest in Xphyto two happy investors talking

Invest in Bionxt, invest in innovation

Learn more about Bionxt’s innovation to impact strategy and get access to Bionxt investor information.